Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (ALGS) has appointed Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. Dr. Wesson brings over 20 years of pharmaceutical development experience to Aligos, having previously served at Kezar Life Sciences and AN2 Therapeutics. His notable achievements include leading drug substance development at Anacor Pharmaceuticals, where he supported the approval and commercial launches of Kerydin and Eucrisa. Dr. Wesson holds a PhD in Organic Chemistry from the University of Cambridge. The appointment comes as Aligos prepares to begin Phase 2 study of ALG-000184 in mid-2025.

Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced the granting of inducement stock options to new employees. The Compensation Committee approved non-qualified stock options to purchase 26,000 shares, granted on June 10, 2025, under the company's 2024 Inducement Plan. These grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), have an exercise price matching Aligos' closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on continued employment.

Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on Thursday, June 5, 2025, at 2:00 PM ET. Interested parties can access the live webcast through the Presentation & Events section of Aligos' investor relations webpage. A replay will remain available for at least 30 days following the presentation.

Aligos Therapeutics (Nasdaq: ALGS) has appointed Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. Kavanaugh brings over 25 years of experience in the biotechnology and pharmaceutical industries. She most recently served as Vice President, Corporate Law & Privacy Officer at Codexis. Her previous roles include being an independent legal consultant for companies like Genentech and Elan Pharmaceuticals, and serving as Practice Group Leader for BioOncology Development Law at Genentech.

The appointment was announced by Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos, who emphasized Kavanaugh's extensive knowledge and broad expertise in legal matters. Kavanaugh holds a BA from UC Berkeley and a JD from Santa Clara University Law School.

Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant for a newly hired employee. The grant, approved by the Company's Compensation Committee, consists of non-qualified stock options to purchase 26,000 shares of company stock.

The options were granted on May 13, 2025, with an exercise price equal to the closing price on the grant date. The shares will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment. This grant was made under Aligos' 2024 Inducement Plan, specifically designed for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).

Aligos Therapeutics (NASDAQ: ALGS) presented positive data from eight presentations at EASL Congress 2025, highlighting significant progress in their liver disease pipeline. The 96-week data for ALG-000184 showed remarkable results in chronic hepatitis B treatment, with 100% of subjects achieving HBV DNA viral suppression. In HBeAg+ subjects, 9/9 achieved HBV DNA suppression by Week 96, while all HBeAg- subjects (11/11) showed rapid decline and sustained suppression by Week 24.

Additionally, their THR-β agonist ALG-055009 demonstrated strong potential in MASH treatment, showing up to 46.2% placebo-adjusted median relative reductions in liver fat at Week 12. Notably, 11/14 subjects on stable GLP-1 agonists treated with ALG-055009 showed liver fat decreases, while maintaining a favorable tolerability profile with gastrointestinal-related adverse events similar to placebo.

Aligos Therapeutics (NASDAQ: ALGS) reported its Q1 2025 financial results and business updates. The company raised over $100M to advance its Phase 2 study of ALG-000184 for chronic hepatitis B virus infection, with dosing expected to begin mid-2025. Key highlights include: Pipeline Progress: - ALG-000184 completed 96-week Phase 1 dosing with promising results - ALG-055009 for MASH treatment showed significant liver fat reduction up to 46.2% in Phase 2a HERALD study - ALG-097558, their pan-coronavirus protease inhibitor, commenced three additional clinical trials Financial Results: - Cash position: $137.9M as of March 31, 2025 - Net income: $43.1M for Q1 2025 - R&D expenses: $14.5M, down from $16.4M in Q1 2024 - G&A expenses: $5.1M, decreased from $6.7M in Q1 2024 Current cash runway extends into second half of 2026.

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotech company specializing in liver and viral disease treatments, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025. The results will be released before U.S. financial markets open.

The company, based in South San Francisco, focuses on developing best-in-class therapies aimed at improving patient outcomes in liver and viral diseases. This upcoming financial report will provide insights into the company's performance during Q1 2025.

Aligos Therapeutics (Nasdaq: ALGS) announced that eight abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025, scheduled for May 7-10, 2025 in Amsterdam. The presentations focus on two key drug candidates:

1. ALG-000184: A potential first/best-in-class small molecule CAM-E for chronic hepatitis B virus infection, with three abstracts highlighting its profound HBV DNA suppression in 96-week studies and resistance barrier analysis.

2. ALG-055009: A potential best-in-class thyroid hormone receptor beta agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with four abstracts demonstrating significant reductions in atherogenic lipids and liver fat, including studies in combination with GLP-1 receptor agonists.